JP2002541800A - 前立腺癌において発現される１３回膜貫通タンパク質 - Google Patents

前立腺癌において発現される１３回膜貫通タンパク質

Info

Publication number
JP2002541800A
JP2002541800A JP2000611669A JP2000611669A JP2002541800A JP 2002541800 A JP2002541800 A JP 2002541800A JP 2000611669 A JP2000611669 A JP 2000611669A JP 2000611669 A JP2000611669 A JP 2000611669A JP 2002541800 A JP2002541800 A JP 2002541800A
Authority
JP
Japan
Prior art keywords
protein
polynucleotide
cancer
antibody
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000611669A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002541800A5 (https=
Inventor
ダニエル イー． アファー，
レネ エス． ハバート，
カハン レオン，
アーサー ビー． ライタノ，
ダグラス シー． サフラン，
Original Assignee
アジェンシス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アジェンシス， インコーポレイテッド filed Critical アジェンシス， インコーポレイテッド
Publication of JP2002541800A publication Critical patent/JP2002541800A/ja
Publication of JP2002541800A5 publication Critical patent/JP2002541800A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2000611669A 1999-04-12 2000-04-12 前立腺癌において発現される１３回膜貫通タンパク質 Pending JP2002541800A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12885899P 1999-04-12 1999-04-12
US60/128,858 1999-04-12
PCT/US2000/010039 WO2000061746A1 (en) 1999-04-12 2000-04-12 13 transmembrane protein expressed in prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007161935A Division JP2007314543A (ja) 1999-04-12 2007-06-19 前立腺癌において発現される１３回膜貫通タンパク質

Publications (2)

Publication Number Publication Date
JP2002541800A true JP2002541800A (ja) 2002-12-10
JP2002541800A5 JP2002541800A5 (https=) 2005-12-15

Family

ID=22437339

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2000611669A Pending JP2002541800A (ja) 1999-04-12 2000-04-12 前立腺癌において発現される１３回膜貫通タンパク質
JP2007161935A Pending JP2007314543A (ja) 1999-04-12 2007-06-19 前立腺癌において発現される１３回膜貫通タンパク質
JP2009269211A Pending JP2010051321A (ja) 1999-04-12 2009-11-26 前立腺癌において発現される１３回膜貫通タンパク質
JP2012269226A Pending JP2013136574A (ja) 1999-04-12 2012-12-10 前立腺癌において発現される１３回膜貫通タンパク質

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2007161935A Pending JP2007314543A (ja) 1999-04-12 2007-06-19 前立腺癌において発現される１３回膜貫通タンパク質
JP2009269211A Pending JP2010051321A (ja) 1999-04-12 2009-11-26 前立腺癌において発現される１３回膜貫通タンパク質
JP2012269226A Pending JP2013136574A (ja) 1999-04-12 2012-12-10 前立腺癌において発現される１３回膜貫通タンパク質

Country Status (6)

Country Link
EP (2) EP2365081A3 (https=)
JP (4) JP2002541800A (https=)
AU (2) AU780061B2 (https=)
CA (1) CA2369413C (https=)
IL (3) IL145775A0 (https=)
WO (1) WO2000061746A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010537671A (ja) * 2007-09-07 2010-12-09 アジェンシス，インコーポレイテッド ２４ｐ４ｃ１２タンパク質に結合する抗体および関連分子

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6943235B1 (en) 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
US7244827B2 (en) 2000-04-12 2007-07-17 Agensys, Inc. Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
JP2004523236A (ja) * 2001-02-16 2004-08-05 インサイト・ゲノミックス・インコーポレイテッド 神経伝達関連タンパク質
EP1565200A4 (en) * 2002-11-27 2009-06-24 Agensys Inc NUCLEIC ACID 24P4C12 AND CORRESPONDING PROTEIN FOR THE TREATMENT AND DETECTION OF CANCER
US8309093B2 (en) 2009-03-06 2012-11-13 Agensys, Inc. Antibody drug conjugates (ADC) that bind to 24P4C12 proteins
JP5122592B2 (ja) * 2010-01-04 2013-01-16 アジェンシス，インコーポレイテッド 癌の処置および検出において有用な２４ｐ４ｃ１２と称される、核酸および対応タンパク質
EP3160513B1 (en) 2014-06-30 2020-02-12 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
US11485972B2 (en) 2017-05-18 2022-11-01 Modernatx, Inc. Modified messenger RNA comprising functional RNA elements

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
DK0489149T3 (da) 1990-06-27 2001-12-27 Univ Princeton Prober til påvisning af mutant P53
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
CH686982A5 (fr) 1993-12-16 1996-08-15 Maurice Stroun Méthode pour le diagnostic de cancers.
DE69532127T2 (de) 1994-07-20 2004-08-26 Genetics Institute, Inc., Cambridge Interaktions-fullensysteme zum nachweis von protein-interaktionen
US5919652A (en) 1994-11-09 1999-07-06 The Regents Of The University Of California Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof
NZ306767A (en) 1995-04-11 2000-03-27 Univ Johns Hopkins Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems
CA2252886C (en) 1996-04-26 2008-02-12 Massachusetts Institute Of Technology Three-hybrid screening assay
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
JP2001502537A (ja) 1996-10-15 2001-02-27 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア ヒト前立腺ガンの進行の動物モデル
US5846722A (en) 1996-10-16 1998-12-08 Terrapin Technologies, Inc. System to detect small molecule/peptide interaction
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
JP2001512013A (ja) * 1997-08-01 2001-08-21 ジェンセット 前立腺に発現される分泌タンパク質の５’ｅｓｔ
WO1999006548A2 (en) * 1997-08-01 1999-02-11 Genset 5'ESTs FOR NON TISSUE SPECIFIC SECRETED PROTEINS
AU8555098A (en) * 1997-08-01 1999-02-22 Genset 5' ests for secreted proteins expressed in testis and other tissues
CA2328895A1 (en) * 1998-06-02 1999-12-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010537671A (ja) * 2007-09-07 2010-12-09 アジェンシス，インコーポレイテッド ２４ｐ４ｃ１２タンパク質に結合する抗体および関連分子

Also Published As

Publication number Publication date
AU2005202143B2 (en) 2007-09-13
IL206604A0 (en) 2011-07-31
AU2005202143A1 (en) 2005-06-09
EP1171595A1 (en) 2002-01-16
AU780061B2 (en) 2005-02-24
WO2000061746A1 (en) 2000-10-19
AU4242500A (en) 2000-11-14
EP2365081A3 (en) 2012-07-18
IL206604A (en) 2013-07-31
IL145775A (en) 2010-11-30
JP2013136574A (ja) 2013-07-11
JP2010051321A (ja) 2010-03-11
JP2007314543A (ja) 2007-12-06
CA2369413C (en) 2013-07-09
EP2365081A2 (en) 2011-09-14
CA2369413A1 (en) 2000-10-19
IL145775A0 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
US7220823B2 (en) Transmembrane protein expressed in prostate and other cancers
JP4373637B2 (ja) ヒト前立腺癌において発現されるｃ型レクチン膜貫通抗原およびその使用
JP2008216267A (ja) ３６ｐ６ｄ５：分泌腫瘍抗原
JP2013136574A (ja) 前立腺癌において発現される１３回膜貫通タンパク質
JP4875671B2 (ja) 前立腺ガンにおいてアップレギュレートされるｇタンパク質結合レセプターおよびその使用
JP5501550B2 (ja) ８４ｐ２ａ９：前立腺癌において高度に発現される前立腺および精巣特異的タンパク質
JP4325943B2 (ja) Ｓｇｐ２８関連分子を使用する、癌の診断および治療
US20040265310A1 (en) Novel prostate-restricted gene expressed in prostate cancer
AU2007249104B2 (en) Transmembrane protein expressed in prostate and other cancers
EP1792989A1 (en) 13 Transmembrane protein expressed in prostate cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20061220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070319

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080214

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080222

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080417

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080425

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080522

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090121

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20090224

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20090703

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110301

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110330

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111013

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111020

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111111

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111213